TherapeuticsMD (TXMD) Misses Q3 EPS by 2c

TherapeuticsMD Expands Commercial and Business Development Leadership

November 3, 2016 4:08 PM EDT

- Dawn Halkuff appointed Chief Commercial Officer -

- Yulii Bogatyrenko appointed Senior Vice President of Business Development -

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business Development. Both executives bring womens health experience and relevant skills to the company in advance of the potential launch of its first bio-identical hormone... More

TherapeuticsMD Announces Third Quarter 2016 Financial Results

November 3, 2016 4:06 PM EDT

- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -

- TX-004HR PDUFA target action date of May 7, 2017 -

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.

Third Quarter and Recent Developments

Announced acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for TX-004HR (conditionally-approved trade name... More